CD274 and non-small cell lung carcinoma: These results led to regulatory approval of first-line ICB monotherapy for NSCLC patients with PDL1 ≥ 50% by the EMA, while the FDA also approved pembrolizumab for patients with PD-L1 ≥ 1%.